psychedelic psychedelic

درمان سرطان ریه

Psychedelic mushroom

Albert Hoffmann, who worked at the Swiss pharmaceutical company Sandoz, was looking for a drug that promoted blood circulation. Then, in 1938, he developed a synthetic substance called Lysergic Acid Diethylamide, which did not have much of the therapeutic effect he had hoped for. However, about five years later, he accidentally discovered the extraordinary efficacy of this synthetic substance. Hoffman, who “accidentally ingested a small amount one day” of the neglected product, “realized that he had created something powerful, and he was both horrified and amazed.”

 

In Central America, wild Psychedelic mushrooms grow, which the Aztecs called ‘Teonanacatl.’ It means ‘Flesh of the Gods.’ They had “ceremonial use” of “this inconspicuous little brown mushroom.” The Spanish Catholics who conquered this place in the 16th century banned ‘magic mushrooms’, so it took about 400 years for them to become known to the world. “In 1955, Gordon Watson, a Manhattan banker and amateur mycologist, tasted these magic mushrooms in a village in southern Mexico.” Two years later, he published a 15-page account of his experience in the weekly magazine ‘Life’, informing the world of “mushrooms that cause strange illusions.” The substance extracted from this mushroom is called ‘Psilocybin.’

 

Michael Pollan (66), an American nonfiction writer and journalist, unexpectedly published a book about LSD and psilocybin. The original book was published in the United States in 2018. Pollan is considered a very well-known author in Korea through books such as “The Omnivore’s Dilemma,” “The Desiring Plant,” and “Second Nature.” He has dealt with a variety of subjects such as nature, gardens, plants, and food. However, the fact that he devoted his writerly attention to drugs that were considered ‘narcotics’ or ‘hallucinogens’ is quite unusual. In his book, he refers to LSD and psilocybin collectively as ‘psychedelics.’ I do not agree with the term ‘hallucinogen’. He explains, “The word ‘psychedelic,’ coined in 1956, is etymologically accurate,” adding, “This word, taken from Greek, means ‘Mind Manifesting.’”

 

As he confesses, the author is not part of the ‘psychedelic generation.’ He was born in 1955 and entered college in the 1970s, so he admits that he spent his youth “in an era when fear-mongering stories about LSD were rampant.” In his late 20s, he confessed that “the only psychedelic experience I had was two or three times using magic mushrooms,” and that “after enduring nausea for a while, I enjoyed four or five hours of hallucinations that were like a nice italicized version of a familiar reality.” . Of course, it was the ‘timid experience’ of an ordinary young man. Rather than “an experience of complete dissolution of the self,” it was “just a low-volume aesthetic experience.”

 

The author, who believed that “matter is the fundamental element of the world and that everything can be explained by physical laws,” confesses that it was only when he was approaching 60 that he “seriously thought about trying LSD for the first time.” Of course, there are many reasons for this. One day at a dinner party, a woman sitting at the end of the table was telling her audience about her acid trip (her hallucinatory experience) and said, “My husband and I do LSD regularly to keep her intellectually stimulated. “It helps our work quite a bit,” she said. “It turned out that she was a renowned psychologist.” Of course, what prompted the author to further open his mind to psychedelics was a paper by a research team at Johns Hopkins University. “I was completely fascinated by the paper. “Their study demonstrated that high doses of psilocybin can be safely and reliably used to produce mystical experiences.”

 

The book describes the history of psychedelics, various controversies, and the medical benefits that have been emerging one after another from various angles. The content and results of research conducted at not only Johns Hopkins, but also Imperial College London, UC Berkeley, and Mount Sinai Icahn School of Medicine are introduced. Researchers and therapists are also interviewed. However, the most interesting point is the author’s actual experience of “turning the handle and stepping inside.” Although the book appears to be an objective document about psychedelics, the author's experiences and thoughts unfold as expressions such as ‘I,’ ‘in my opinion,’ and ‘from what I have experienced’ appear frequently. He also describes the “overwhelming hallucinations” and “completely open dream-like state” he experienced.

 

According to the authors, “Most of the notorious hazards are exaggerated or untrue. It is virtually impossible to die from an overdose of LSD or psilocybin, and neither drug is addictive.” Rather, she “treats depression and addiction” and “offers true insight” through “expansion of consciousness.” It could also “improve healthy people” as a kind of “mental gym”. Of course, the author emphasizes that this insight or improvement does not come from the drug itself, but “comes from our mind.” “Psychedelics just opened the door.”

 

At the end of the book, the author says, “I sincerely hope that psychedelics will one day be more widely available and not limited to sick people.” But there is a clue. “It’s not that I just want it to be legalized,” he said, pointing out, “It’s also true that people who use psychedelics tend to do stupid and dangerous things.” This is a warning against a so-called ‘bad trip’. This is also the reason why “careful clinical screening” and “assistance from experienced guides” are mentioned. The author defines this book as “the story of the renaissance of LSD and psilocybin.”


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/2/16 ساعت: ۱۷ توسط:spudgene2 :

psychedelic_treatment

Augmented therapies: psychedelic substances, scientific evidence (Henrik Jungaberle)

Augmented therapies combine therapy and the taking of psychedelic substances. In Germany, the development of this emerging technique is supported by the MIND Foundation, which participates in scientific studies, organizes an international congress and trains doctors. A request is even underway for doctors in training to be able to experiment with these psychedelic substances themselves. It must be said that the clinical results of this innovative treatment look promising, particularly for the treatment of recalcitrant depression. Explanations from Dr Jungaberle, director of the MIND Foundation.

 

 

We created this non-profit organization five years ago to support research, scientific communication and continuing education for doctors and psychotherapists. For two years, OVID Clinics has provided a clinical setting in which we can treat patients.

 

We are probably the first organization in the world, in the field of psychedelics, whose work is entirely based on scientific evidence. We consider psychedelic treatments to lie exactly at the intersection of medicine and psychotherapy. And we want to bring this form of therapy to the heart of international medicine.

 

 

What is augmented psychotherapy?

 

We have a certain conception of psychedelic therapy, and it differs from that defended, for example, by Stan Grof 1 in the 1960s and 1970s. We believe that psychedelic therapy is a very particular form of psychotherapy. But here, the medical perspective joins the psychotherapeutic perspective.

 

The pharmaceutical product used is special because it generates particularly profound experiences in patients, and this requires a framework. This framework, which we believe to be rigorous, beneficial to patients and also ethical, is called psychotherapy.

 

What does “increase” mean? This is what psychiatrists know when certain medications are potentiated, generally by another substance. For us, this means that psychotherapy and psychedelics influence each other in their effects.

 

This may not be easy to imagine for someone who usually only works in organic medicine, but it's actually easy to explain: The effect of psychedelics depends on environment and attitude interior of the person who absorbs them. This means that there is an increase in this direction.

 

Conversely, this also means that the effect of the therapy depends on the psychedelic. This, for example, enormously influences the relationship between therapist and patient. It can accelerate the establishment of the relationship or even strengthen it.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/2/4 ساعت: ۱۷ توسط:spudgene2 :

pharmaceutical_grade_psychedelics

Pharmaceutical grade psychedelics refer to psychedelic substances that are produced and manufactured to meet pharmaceutical quality standards. This term is often used to describe psychedelics that are being researched and developed for potential medical or therapeutic applications.

In recent years, there has been a resurgence of interest in the therapeutic potential of psychedelics such as psilocybin, MDMA, and LSD. These substances have shown promise in the treatment of mental health conditions such as depression, post-traumatic stress disorder (PTSD), and addiction. As a result, there has been a growing effort to develop pharmaceutical grade versions of these substances for use in clinical settings.

Producing pharmaceutical grade psychedelics involves rigorous quality control measures to ensure purity, potency, and consistency. This includes adhering to Good Manufacturing Practices (GMP) and conducting extensive testing to meet regulatory requirements. Pharmaceutical grade psychedelics are typically produced in controlled laboratory environments to minimize contamination and ensure precise dosing.

The development of pharmaceutical grade psychedelics involves conducting clinical trials to assess their safety and efficacy. These trials are conducted under strict protocols and guidelines to ensure the well-being of participants and to generate reliable data. The goal is to establish the therapeutic potential of these substances and obtain regulatory approval for their use in specific medical contexts.

It's important to note that while pharmaceutical grade psychedelics are being researched and developed, they are not yet widely available for clinical use. The regulatory landscape surrounding these substances varies across countries and regions, and their use outside of approved research settings is generally illegal.

The emergence of pharmaceutical grade psychedelics represents a significant shift in the perception and understanding of these substances. Through rigorous scientific investigation, there is hope that they may become approved treatments for various mental health conditions, offering new possibilities for individuals who have not found relief through traditional therapies. However, it is essential to continue conducting research, ensuring safety protocols, and navigating regulatory processes to fully explore the potential benefits and risks of these substances in a medical context.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/2/2 ساعت: ۱۲ توسط:spudgene2 :

natural_pharmaceutical_grade_psychedelics

The term "natural pharmaceutical grade psychedelics" refers to psychedelic substances that are derived from natural sources and meet pharmaceutical quality standards. These substances are obtained from plants or fungi and undergo rigorous manufacturing processes to ensure purity, consistency, and compliance with pharmaceutical regulations.

Several natural psychedelic substances have gained attention for their potential therapeutic applications, including psilocybin from psychedelic mushrooms, mescaline from the peyote cactus, and DMT (dimethyltryptamine) from various plant sources like ayahuasca. These substances have a long history of traditional use in cultural and spiritual practices, and recent scientific research has explored their therapeutic potential.

To achieve the pharmaceutical grade designation, natural psychedelic substances undergo a series of manufacturing steps. This includes extraction and purification processes to isolate the active compounds and remove impurities. Quality control measures, such as testing for potency and contaminants, are implemented to ensure consistent and reliable products.

The use of natural pharmaceutical grade psychedelics in clinical settings involves conducting rigorous research and clinical trials to assess their safety and efficacy. These studies are designed to gather scientific evidence supporting the therapeutic benefits of these substances for specific mental health conditions. They aim to establish optimal dosing protocols, understand potential risks, and evaluate long-term effects.

It's important to note that the regulation and legal status of natural pharmaceutical grade psychedelics vary across countries and regions. While some jurisdictions have taken steps to decriminalize or legalize certain substances for medical or research purposes, strict regulatory frameworks are in place to ensure their controlled and responsible use.

The exploration of natural pharmaceutical grade psychedelics represents an intersection of traditional wisdom and modern scientific approaches. By harnessing the potential of these natural substances within a pharmaceutical framework, researchers and medical professionals aim to unlock new avenues for mental health treatment and provide alternative options for individuals who have not found relief through conventional therapies.

However, it is crucial to approach natural pharmaceutical grade psychedelics with caution. These substances can induce profound experiences and have the potential for both positive and challenging effects. Responsible use, proper screening, and therapeutic support are essential to ensure the safety and well-being of individuals who may benefit from their therapeutic potential.

As research continues and regulatory landscapes evolve, natural pharmaceutical grade psychedelics hold promise as potential tools in the field of mental health treatment. Their exploration represents a dynamic and ongoing effort to understand the therapeutic benefits, risks, and appropriate applications of these natural substances in a clinical context.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/2/2 ساعت: ۱۲ توسط:spudgene2 :

psychedelic_mushrooms

Psychedelic mushrooms, also known as magic mushrooms or shrooms, are a type of fungi that contain psychoactive compounds such as psilocybin and psilocin. These natural substances can induce profound alterations in perception, cognition, and mood, leading to a hallucinogenic experience.

The history of psychedelic mushroom use dates back thousands of years, with evidence of their ceremonial and spiritual use by indigenous cultures in various parts of the world. In recent decades, they have gained popularity as recreational substances and have also attracted scientific interest for their potential therapeutic effects.

When consumed, psychedelic mushrooms can produce a range of effects. Users often report visual hallucinations, changes in sensory perception, and an altered sense of time and space. The experience can be intensely introspective, leading to profound insights and a heightened sense of connectedness with oneself, others, and the universe.

The psychoactive compounds in psychedelic mushrooms interact with serotonin receptors in the brain, particularly the 5-HT2A receptors, leading to alterations in brain activity and neurotransmitter release. These effects are thought to underlie the profound and often transformative experiences associated with their use.

Beyond their recreational use, psychedelic mushrooms have shown promise in the field of mental health. Research suggests that they may have therapeutic potential for the treatment of various conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). Studies have explored their ability to promote neuroplasticity, enhance emotional processing, and induce mystical or spiritual experiences that can have lasting positive effects on well-being.

It's important to note that the use of psychedelic mushrooms carries risks and should be approached with caution. The intensity of the experience and the potential for psychological and emotional challenges during a trip make set and setting crucial factors to consider. Additionally, the legal status of psychedelic mushrooms varies across jurisdictions, and their use can have legal consequences.

As with any psychoactive substance, responsible use, informed decision-making, and harm reduction practices are essential. It is advisable to seek guidance from experienced individuals or professionals knowledgeable about psychedelic substances before exploring their use for recreational or therapeutic purposes.

Overall, psychedelic mushrooms are intriguing organisms that have captivated human interest for centuries. Whether used recreationally or explored for their therapeutic potential, they continue to be a subject of scientific research and cultural fascination, offering a unique and often transformative experience for those who choose to explore their effects.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/2/2 ساعت: ۱۲ توسط:spudgene2 :

Psychedelic therapy

In recent years, the field of mental health has witnessed a resurgence of interest in a novel approach known as psychedelic therapy. Combining the use of carefully administered psychedelic substances with therapeutic support, this groundbreaking treatment modality has shown remarkable promise in addressing a range of mental health conditions. In this article, we delve into the world of psychedelic therapy, exploring its history, mechanisms of action, current research, and potential benefits.

The History of Psychedelic Therapy:

Psychedelic therapy has roots that stretch back centuries, with indigenous cultures incorporating plant-based psychedelics into spiritual and healing practices. Modern psychedelic therapy, however, emerged in the mid-20th century, pioneered by researchers like Timothy Leary, Richard Alpert (Ram Dass), and Stanislav Grof. Early studies demonstrated promising results, but the subsequent cultural backlash and legal restrictions hindered further exploration until recent years.

Understanding Psychedelic Substances:

Psychedelic therapy primarily utilizes substances such as psilocybin (found in magic mushrooms), lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT). These substances work by modulating serotonin receptors in the brain, leading to altered states of consciousness, heightened introspection, and increased emotional receptivity.

The Mechanisms of Healing:

Psychedelic therapy's therapeutic effects stem from the profound psychological experiences induced by the substances. These experiences often include a sense of interconnectedness, ego dissolution, and the surfacing of deeply rooted emotions and memories. By facilitating this process, psychedelic therapy allows individuals to gain new perspectives, process traumatic experiences, and foster personal growth.

Conditions and Disorders Addressed:

Research has shown promising results in the application of psychedelic therapy for various mental health conditions, including treatment-resistant depression, post-traumatic stress disorder (PTSD), anxiety disorders, addiction, and end-of-life distress in terminally ill patients. Preliminary studies indicate that psychedelic therapy can produce long-lasting positive changes and improve overall well-being.

The Therapeutic Process:

Psychedelic therapy involves a structured and supportive environment, typically with trained therapists. This includes preparation sessions, the administration of the psychedelic substance in a controlled setting, and integration sessions afterward to process and integrate the experiences. The therapeutic alliance and careful integration are crucial elements that maximize the benefits of psychedelic therapy.

Current Research and Legal Developments:

In recent years, there has been a resurgence of scientific interest in psychedelic therapy, with rigorous clinical trials demonstrating its safety and efficacy. These studies have prompted regulatory agencies to revisit restrictions, leading to breakthroughs in the legal status of psychedelic substances in some jurisdictions. Ongoing research aims to further elucidate the therapeutic potential of psychedelic therapy.

Ethical Considerations and Risks:

While psychedelic therapy holds significant promise, it is not without ethical considerations and potential risks. Ensuring proper screening, trained professionals, appropriate dosing, and comprehensive integration are essential to minimize adverse effects and maximize therapeutic outcomes. Additionally, the potential for misuse and recreational use emphasizes the importance of responsible and controlled administration.

Conclusion:

Psychedelic therapy represents a paradigm shift in mental health treatment, offering a unique approach to healing and personal transformation. With ongoing research, growing acceptance, and evolving regulations, the therapeutic potential of psychedelics is poised to reshape the landscape of mental healthcare, providing new avenues of hope and healing for individuals around the world.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/1/29 ساعت: ۱۷ توسط:spudgene2 :

psychedelic treatment

Psychedelic treatment refers to a therapeutic approach that utilizes psychedelic substances in a controlled and supportive environment to address various mental health conditions. The treatment involves the administration of substances like psilocybin, LSD, or MDMA under the guidance of trained therapists. Psychedelic treatment aims to induce altered states of consciousness that facilitate profound psychological experiences, leading to introspection, emotional breakthroughs, and transformative insights. These experiences can catalyze healing, personal growth, and positive changes in individuals. Ongoing research and clinical trials are exploring the safety, efficacy, and therapeutic potential of psychedelic treatment for conditions such as depression, PTSD, anxiety disorders, and addiction. The integration of these experiences through follow-up sessions with therapists is an integral part of the treatment process, allowing individuals to process and integrate the insights gained during the psychedelic session into their daily lives. The growing interest in psychedelic treatment is shaping the field of mental health care, offering new possibilities for healing and transformation.

Historical Context:

The use of psychedelic substances for therapeutic purposes has a rich historical context. Indigenous cultures and ancient civilizations have employed naturally occurring psychedelic substances in rituals and healing practices for centuries. In recent history, the 1950s and 1960s saw notable research on psychedelics, which was interrupted by political and cultural shifts. However, the past few decades have witnessed a renewed interest in exploring the therapeutic potential of these substances.

Mechanisms of Action:

Psychedelic substances interact with the brain's serotonin receptors, leading to altered states of consciousness. They can modulate neural networks and enhance communication between brain regions that are typically less connected. This increased connectivity may facilitate novel insights, emotional processing, and the exploration of the self, leading to therapeutic effects.

Conditions Addressed:

Psychedelic treatment has shown promise in addressing various mental health conditions. Research has focused on treatment-resistant depression, anxiety disorders, PTSD, addiction, and existential distress in individuals with life-threatening illnesses. Studies have reported significant reductions in symptoms, improved mood, increased well-being, and enhanced quality of life following psychedelic treatment.

Therapeutic Process:

Psychedelic treatment typically involves careful preparation and a supportive therapeutic setting. Sessions are conducted in a controlled environment with trained therapists who offer guidance, support, and a sense of safety throughout the experience. The therapists help individuals navigate the psychedelic journey, fostering a trusting and therapeutic relationship. Integration sessions follow the experience to help individuals process and integrate their insights into their lives effectively.

Research and Clinical Trials:

There has been a resurgence of scientific interest in psychedelic treatment, leading to a growing body of research and clinical trials. Rigorous studies are investigating the safety, efficacy, optimal dosing, and long-term effects of psychedelic treatment. The results have been promising, and regulatory bodies are increasingly recognizing the therapeutic potential of psychedelics, paving the way for expanded research and access to treatment.

 

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/1/29 ساعت: ۱۷ توسط:spudgene2 :

Psychedelic therapy for OCD

Psychedelic therapy has emerged as a potential treatment approach for individuals with obsessive-compulsive disorder (OCD). Psychedelics such as psilocybin, LSD, and ayahuasca are being studied for their therapeutic effects on various mental health conditions, including OCD. Psychedelic therapy involves the administration of a moderate to high dose of a psychedelic substance in a controlled and supportive therapeutic setting, accompanied by preparatory and integration sessions.

Preliminary research suggests that psychedelic therapy may offer unique benefits for individuals with OCD. The altered state of consciousness induced by psychedelics can lead to a temporary dissolution of the rigid patterns of thought and behavior characteristic of OCD. This can provide individuals with a different perspective on their obsessive thoughts and compulsive behaviors, potentially leading to a reduction in symptoms and an increased sense of psychological flexibility.

Psychedelic therapy for OCD often involves a combination of the pharmacological effects of the psychedelic substance and the therapeutic support provided by trained professionals. The therapy session is typically guided by therapists who help individuals navigate their psychedelic experience and provide emotional support and guidance. Integration sessions following the psychedelic session are crucial for individuals to make sense of their experiences and apply insights gained during the session to their daily lives.

It's important to note that psychedelic therapy for OCD is still in the early stages of research, and more studies are needed to establish its safety, efficacy, and optimal protocols. The therapy should only be conducted under the supervision of trained professionals in a controlled environment. Additionally, psychedelic therapy is not a standalone treatment but should be integrated into a comprehensive treatment plan that may include other therapeutic modalities and support systems.

Despite the ongoing research, early findings suggest that psychedelic therapy holds promise for individuals with OCD. Studies have reported positive outcomes, including a reduction in OCD symptoms, improved quality of life, and increased psychological well-being. However, it's crucial to approach psychedelic therapy with caution and ensure that it is undertaken within a legal and ethical framework, with appropriate safeguards in place.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/1/29 ساعت: ۱۷ توسط:spudgene2 :

Pharmaceutical_Grade_Psychedelics

“The world urgently needs a new way to treat mental health issues, and at PsyRx we believe psychedelics are a big part of the solution,” says Itay Hecht.

Hecht is CEO and co-founder of this Israeli company, which is developing standardized pharmaceutical grade psychedelics from natural sources — not synthetics — as active pharmaceutical ingredients.

Using an agro-medical bioreactor invented at the Hebrew University Faculty of Agriculture, PsyRx produces psychedelic botanic extracts psilocybin (from “magic” mushrooms) and ibogaine (from the root bark of the iboga shrub).

Psilocybin has been shown to have positive effects in treating depression, anxiety and addiction, and has been suggested as a potential treatment for obesity, PTSD, cluster headaches and more.

Ibogaine has shown promise as an anti-addiction drug, among other indications. PsyRx is focusing on its potential to improve current SSRI (selective serotonin reuptake inhibitor) antidepressants.

“SSRIs have some very bad side effects on libido and appetite, and patients often stop using them. We believe adding a microdose of ibogaine will counter those effects and make a better drug,” Hecht says, emphasizing that microdoses of psychedelic substances do not cause hallucinations.

“We are starting small animal trials soon to check safety and efficacy. Hopefully, in a year’s time, we can start human trials” to test this ibogaine application, he tells ISRAEL21c.

ON-TREND

Adding psychedelics to mainstream drugs may seem a bit “out there,” but in fact it’s on-trend.

According to market intelligence report CB Insights, funding for psychedelic medicine companies is growing rapidly as traditional pharma giants see declines in return on investment for drug R&D and are interested in exploring alternative products. Consumer interest in hallucinogenic drugs also is growing, according to this report.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/1/26 ساعت: ۱۵ توسط:spudgene2 :

Pharmaceutical_Grade_Psychedelics

“The world urgently needs a new way to treat mental health issues, and at PsyRx we believe psychedelics are a big part of the solution,” says Itay Hecht.

Hecht is CEO and co-founder of this Israeli company, which is developing standardized pharmaceutical grade psychedelics from natural sources — not synthetics — as active pharmaceutical ingredients.

Using an agro-medical bioreactor invented at the Hebrew University Faculty of Agriculture, PsyRx produces psychedelic botanic extracts psilocybin (from “magic” mushrooms) and ibogaine (from the root bark of the iboga shrub).

Psilocybin has been shown to have positive effects in treating depression, anxiety and addiction, and has been suggested as a potential treatment for obesity, PTSD, cluster headaches and more.

Ibogaine has shown promise as an anti-addiction drug, among other indications. PsyRx is focusing on its potential to improve current SSRI (selective serotonin reuptake inhibitor) antidepressants.

“SSRIs have some very bad side effects on libido and appetite, and patients often stop using them. We believe adding a microdose of ibogaine will counter those effects and make a better drug,” Hecht says, emphasizing that microdoses of psychedelic substances do not cause hallucinations.

“We are starting small animal trials soon to check safety and efficacy. Hopefully, in a year’s time, we can start human trials” to test this ibogaine application, he tells ISRAEL21c.

ON-TREND

Adding psychedelics to mainstream drugs may seem a bit “out there,” but in fact it’s on-trend.

According to market intelligence report CB Insights, funding for psychedelic medicine companies is growing rapidly as traditional pharma giants see declines in return on investment for drug R&D and are interested in exploring alternative products. Consumer interest in hallucinogenic drugs also is growing, according to this report.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/1/26 ساعت: ۱۵ توسط:spudgene2 :

psychedelic_mushrooms

The small village of San José del Pacifico doesn't actually have much to offer. Nevertheless, thousands of backpackers are drawn to the highlands of Oaxaca every year. The reason is psychedelic mushrooms. The "magic mushrooms" are an integral part of the indigenous culture, which is why their consumption is tolerated here. In the rest of the world, “magic mushrooms” are currently making a comeback. On the one hand, as a lifestyle drug that allows stressed managers to experience their limits without much effort. But also as a research object: The active ingredient psilocybin contained in the mushrooms is said to help with depression or anxiety disorders.

 

Tourists come for the psychedelic mushrooms

In San José del Pacifico they are everywhere. And many come – especially for her. "Why am I here? Because of the mushrooms. And the mountains," says a German tourist. "Actually all backpackers who come here take them. But I don't know yet. We were still skeptical. And we actually decided no," say two other tourists. Psychedelic mushrooms. Or magic mushrooms. "We came here to take the mushrooms. We did that yesterday," says a young woman. Another said: "We thought it all made some sense. That our hostel was designed specifically for this. Everything was so... forest-like. You can see why people do it here of all places."

 

Here in the highlands of Oaxaca, psychedelic mushrooms are part of the indigenous culture. Therefore their consumption is tolerated. And almost the entire village lives from the tourists' borderline experiences. Navarro too. He offers mushroom trips in his garden. And in the way that corresponds to the indigenous ritual. Only after a sweat treatment in the Temazcal, the traditional Mexican sauna. "If you want to do it right, you first have to cleanse your body and your mind," explains Navarro Temzcaliero. "My Temazcal is medicine. It makes you breathe better, hear better, it relaxes you, you're no longer tired, you're no longer in pain. It brings you into the moment." Be in the here and now. In harmony with nature. That is the goal. But tourists keep coming to him who just want to experience the crazy mushroom trip. Without ritual. Without Temazcal. In the village the mushrooms are sold like chewing gum. But here the Temazcal is part of it. If someone only wants the mushrooms and no Temazcal, then I say: the drug dealer is waiting on the street. I am a medicine man.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/1/26 ساعت: ۱۵ توسط:spudgene2 :

psychedelic_treatment

THE PSYCHOTHERAPEUTIC POINT OF VIEW OF PSYCHEDELIC-ASSISTED TREATMENT

 

The psychotherapeutic setting offers a highly controllable and supportive environment that most likely differs from the patient's other past and present environments. As time passes, the patient regularly exposed to this therapeutic environment gradually adapts to it. In doing so, it slowly updates its high-level forecasts that were formed in less controllable environments and therefore indicate large uncertainty. Because the therapeutic environment strongly contradicts the rigid prediction of uncontrollability and uncertainty, the sensory prediction error becomes larger and larger. At a certain point, the sensory inputs that signal safety and support can no longer be explained, initiating an updating process.

 

Psychedelics appear to amplify the restorative effect of real relationships. From a psychological point of view, we have already said that psychedelics tend to increase feelings of connection with the therapist. The socializing effect of MDMA is typical.

 

Psychedelics (to some extent) give us what we expect to get from them, like a placebo. This is not a new idea. Weil (1972) described psychedelics as a kind of active placebo: while they certainly do something, most of what it is may come from the users themselves.

 

Grof (2008) argues that “psychedelics function more or less as nonspecific catalysts and amplifiers of the psyche.” Finally, Matthew Johnson, quoted by Pollan (2018) says about psychedelic treatment: “Whatever we are delving into here, it is in the same realm as placebo. But a placebo on a rocket.”

 

Psychotherapy has also been described as a placebo (open-label). Consequently, we can say that a psychedelic session enhances the placebogenic effects of psychotherapy, making psychedelic-assisted treatment a sort of super placebo.

 

Psychotherapy (co)defines a patient's set and setting, i.e. his internal and external environment: it induces expectations of repair and provides a safe environment. When the brain enters an anarchic state due to the supposed effects of psychedelics, the bottom-up signals sent from these internal and external environments become more influential. In this way, the patient should be able to transfer the safety and controllability of the therapeutic environment to his own generative model, enhancing the path of the real relationship. Similarly, psychedelics also appear to enhance the expectation pathway.

 

On the one hand, it is hypothesized that the impact of restorative expectations is less limited by higher-level forecasts. Any positive basic feelings and attitudes a patient may have towards a psychedelic experience tend to be amplified with psychedelics.


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1403/1/26 ساعت: ۱۵ توسط:spudgene2 :

Psychedelic Mushroom

Psilocybe cubensis

Singer noted that Psilocybe cubensis had psychoactive properties in 1949.

In Australia, the use of psychoactive mushrooms grew rapidly between 1969 and 1975.

In a 1992 paper, locals and tourists in Thailand were reported to consume P. cubensis and related species in mushroom omelets—particularly in Ko Samui and Ko Pha-ngan. At times, omelets were adulterated with LSD, resulting in prolonged intoxication. A thriving subculture had developed in the region. Other localities, such as Hat Yai, Ko Samet, and Chiang Mai, also had some reported uغير مجاز مي باشدe.

In 1996, jars of honey containing Psilocybe cubensis were confiscated at the Dutch-German border. Upon examination, it was revealed that jars of honey containing psychedelic mushrooms were being sold at Dutch coffee shops.

P. cubensis is probably the most widely known of the psilocybin-containing mushrooms used for triggering psychedelic experiences after ingestion. Its major psychoactive compounds are:

Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine)
Psilocin (4-hydroxy-N,N-dimethyltryptamine)
Baeocystin (4-phosphoryloxy-N-methyltryptamine)
Norbaeocystin (4-phosphoryloxytryptamine)
Aeruginascin (N,N,N-trimethyl-4-phosphoryloxytryptamine)
The concentrations of psilocin and psilocybin, as determined by high-performance liquid chromatography, are in the range of 0.14–0.42% (wet weight) and 0.37–1.30% (dry weight) in the whole mushroom 0.17–0.78% (wet weight) and 0.44–1.35% (dry weight) in the cap, and 0.09%–0.30% (wet weight) and 0.05–1.27% (dry weight) in the stem, respectively.[17] For quickly and practically measuring the psychoactive contents of most healthy Psilocybe cubensis varieties, it can generally be assumed that there is approximately 15 mg (+/- 5 mg) of psilocybin per gram of dried mushroom.[18] Furthermore, due to factors such as age and storage method, the psilocybin and psilocin content of a given sample of mushrooms will vary.

Individual body composition, brain chemistry and psychological predisposition play a significant role in determining appropriate doses. For a modest psychedelic effect, a minimum of one gram of dried Psilocybe cubensis mushrooms is ingested orally, 0.25–1 gram is usually sufficient to produce a mild effect, 1–2.5 grams usually provides a moderate effect and 2.5 grams and higher usually produces strong effects.[19] For most people, 3.5 dried grams (1/8 oz) would be considered a high dose and may produce an intense experience; this is, however, typically considered a standard dose among recreational users. Body composition (usually weight) should be taken into account when calculating doغير مجاز مي باشدe. For many individuals, doses above three grams may be overwhelming. For a few rare people, doses as small as 0.25 gram can produce full-blown effects normally associated with very high doses. For most people, however, that dose level would have virtually no effects.

There are many different ways to ingest Psilocybe cubensis. Users may prefer to take them raw, freshly harvested, or dried and preserved. It is also possible to prepare culinary dishes such as pasta or tea with the mushrooms. However, the psychoactive compounds begin to break down rapidly at temperatures exceeding 100 °C (212 °F).[20] Another method of ingestion known as "Lemon Tekking" involves combining pulverized Psilocybe cubensis with a concentrated citrus juice with a pH of ~2. Many users believe that a considerable amount of the psilocybin will have been dephosphorylated into psilocin, the psychoactive metabolite, by citric acid. However, this claim is not substantiated by the literature on the metabolism of psilocybin, as dephosphorylation is known to be mediated by the enzyme alkaline phosphatase in humans.[21] It is therefore more likely that citric acid mostly helps in breakdown of mushroom cells, aiding in digestion and psilocybin release.[citation needed] The "Lemon Tekk" method of consumption results in a more rapid onset and can offer easier digestion or reduced "come-up pressure" associated with raw consumption.[22] Psilocybe cubensis can also be taken in conjunction with other botanicals such as turmeric, ginger, and black pepper. A 2019 study observed turmeric to act as a mild MAOI, which, when combined with psilocin, potentiates the biochemical interactions between serotonin receptors and psilocin, creating an entourage effect.

Upon ingestion, effects usually begin after approximately 20–60 minutes (depending on the method of ingestion and stomach contents) and may last from four to ten hours, depending on doغير مجاز مي باشدe and individual biochemistry. Visual distortions often occur, including walls that seem to breathe, a vivid enhancement of colors, and the animation of organic shapes.[citation needed]

The effects of high doses can be overwhelming depending on the particular phenotype of cubensis, grow method, and the individual. It is recommended not to eat wild mushrooms without properly identifying them as they may be poisonous. In particular, similar species include mushrooms of the genus Galerina and Pholiotina rugosa—all potentially deadly—and Chlorophyllum molybdites. All of these grow in pastures, a similar habitat to that preferred by P. cubensis.

 


برچسب:
امتیاز دهید:
رتبه از پنج: <~PostRate~>
بازدید: <~PostViwe~>

+ نوشته شده: 1402/8/9 ساعت: ۱۶ توسط:spudgene2 :